|
April. 22, 2023 |
|
|
Dec. 05, 2023 |
|
|
jRCT2031230051 |
Phase 2 Allergen Challenge Trial of NTa53 in Patients with Allergic Conjunctivitis |
|
Phase 2 Conjunctival Allergen Challenge Trial of NTa53 |
Hasunuma Tomoko |
||
Kitasato University Kitasato Institute Hospital |
||
5-9-1 Shirokane,Minato-ku, Tokyo, Japan |
||
+81-3-5791-6350 |
||
t-hasu@insti.kitasato-u.ac.jp |
||
Research & Development |
||
Nitto Medic Co., Ltd. |
||
1-14-1 Yasuuchi, Yatsuo-machi, Toyama-city, Toyama, Japan |
||
+81-76-455-3541 |
||
clinical@nittomedic.co.jp |
Complete |
June. 20, 2023 |
||
| June. 20, 2023 | ||
| 40 | ||
Interventional |
||
randomized controlled trial |
||
double blind |
||
dose comparison control |
||
crossover assignment |
||
treatment purpose |
||
-Japanese adult between the age of 18 to under 65 years at the time of the informed consent |
||
-Eye disease other than allergic conjunctivitis is present and requires treatment. |
||
| 18age old over | ||
| 65age old not | ||
Both |
||
Allergic Conjunctivitis |
||
NTa53 and placebo administration, and allergen challenge |
||
Efficacy (Subjective Ocular Symptom Score and Objective Findings Score), Safety |
||
| Nitto Medic Co., Ltd. |
| The IRB of Kitasato University Shirokane Campus | |
| 5-9-1 Shirokane,Minato-ku, Tokyo | |
+81-3-5791-6177 |
|
| irb-pt@insti.kitasato-u.ac.jp | |
| Approval | |
April. 14, 2023 |
No |
none |